Drug Trial Radar · NCT05021900
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 13, 2021
Primary completion
Mar 31, 2023
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.
Conditions
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
Interventions
Tenalisib 800mgDrug
Tenalisib will be administered 800mg BID, orally
Tenalisib 1200mgDrug
Tenalisib will be administered 1200mg BID, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Without Disease ProgressionTime frame: Approximately 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
High Technology Hospital Medcenter
Batumi, Georgia
LLC Caucasus Medical Center
Tbilisi, Georgia
Simon Khechinashvili University Hospital
Tbilisi, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.